Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of once-daily fluticasone furoate + umeclidinium + vilanterol versus dual combinations in COPD
2013-003075-35Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone, umeclidinium and vilanterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Annual rate of on-treatment moderate and severe exacerbations comparing FF/UMEC/VI with UMEC/VI. Started Jun 2014; status: completed.
02
Drugs
fluticasoneumeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2013-003075-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003075-35.